Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

/0 Comments/in /by

Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Pei, Tracy McGowan

Click here to read more.

Preserving Independent Urology: LUGPA’s First Decade

/0 Comments/in /by

Neal D. Shore, Deepak A. Kapoor, Evan R. Goldfischer, David C. Chaikin, Earl L. Walz, Jonathan Henderson, Richard G. Harris, Robert D. Asinof, Gary M. Kirsh

Click here to read more.

A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use

/0 Comments/in /by

Neal Shore, Sreevalsa Appukkuttan, Krishna Tangirala, Svetlana Babajanyan, Lonnie Wen, Stacey Simmons

Click here to read more.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

/0 Comments/in /by

Andrew J. Armstrong, MD, ScM; Russell Z. Szmulewitz, MD; Daniel P. Petrylak, MD; Jeffrey Holzbeierlein, MD; Arnauld Villers, MD; Arun Azad, MBBS, PhD; Antonio Alcaraz, MD, PhD; Boris Alekseev, MD; Taro Iguchi, MD, PhD; Neal D. Shore, MD; Brad Rosbrook, MS; Jennifer Sugg, MS; Benoit Baron, MS; Lucy Chen, MD; and Arnulf Stenzl, MD

Click here to read more.

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide

/0 Comments/in /by
Full Title: Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal Shore, Christian Zurth, Robert Fricke, Hille Gieschen, Kristina Graudenz, Mikko Koskinen, Bart Ploeger, Jonathan Moss, Olaf Prien, Gustavo Borghesi, Oana Petrenciuc, Teuvo L. Tammela, Iris Kuss, Frank Verholen, Matthew R. Smith, Karim Fizazi

Click here to read more.

Real-World Outcomes of Sipuleucel-T Treatment in PROCEED, a Prospective Registry of Men With Metastatic Castration-Resistant Prostate Cancer

/0 Comments/in /by

Celestia S. Higano, MD1; Andrew J. Armstrong, MD, ScM2,3; A. Oliver Sartor, MD4; Nicholas J. Vogelzang, MD5; Philip W. Kantoff, MD6; David G. McLeod, MD, JD7; Christopher M. Pieczonka, MD8; David F. Penson, MD, MPH9,10; Neal D. Shore, MD11; Jeffrey Vacirca, MD12; Raoul S. Concepcion, MD13; Ronald F. Tutrone, MD14; Luke T. Nordquist, MD15; David I. Quinn, MBBS, PhD16; Vahan Kassabian, MD17; Mark C. Scholz, MD18; Matt Harmon, JD19; Robert C. Tyler, PhD20; Nancy N. Chang, PharmD20; Hong Tang, MD20; and Matthew R. Cooperberg, MD, MPH21,22

Click here to read more.

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate with Prednisone Tolerability (REAAcT)

/0 Comments/in /by

Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Peig, Tracy McGowan

Click here to read more

Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States

/0 Comments/in /by

Jeremy B. Shelton, Thomas A. Paivanas, Phil Buffington, Stephen R. Ruyle, Edward S. Cohen, Richard Natale II, Bryan Mehlhaff, Ronald Suh, Timothy J. Bradford, Alec S. Koo, Lorna Kwan, Neal Shore

Click here to read more

 

Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States

/0 Comments/in /by
Jeremy B. Shelton, Phil Buffington, Richard Augspurger, Franklin Gaylis, Todd Cohen, Bryan Mehlhaff, Ronald Suh, Timothy J. Bradford, Lorna Kwan, Alec S. Koo,  Neal Shore

to read more. click here